MRNA vaccine for treating lung cancer and bone metastasis thereof as well as preparation method and application of mRNA vaccine
The invention discloses an mRNA (messenger Ribonucleic Acid) vaccine for treating lung cancer and bone metastasis thereof as well as a preparation method and application of the mRNA vaccine. Belongs to the technical field of nano-drug preparations and nucleic acid vaccines. The vaccine can realize co-entrapment of the TLR4 agonist monophosphoryl lipid A (mPLA) and mRNA (messenger ribonucleic acid). The particle size is 60-600nm, the Zeta potential is + 8 to + 37mV, the encapsulation efficiency is 60-93%, and the mRNA drug loading capacity is 7.5-20%. The mRNA vaccine constructed by the invention can be administered in a subcutaneous/muscle/nasal mucosa way, stimulate DCs cells to be mature, polarize M2 type macrophages into M1 type macrophages and activate the ADCC effect of NK cells, and multiple immune pathways synergistically play an anti-tumor treatment effect. Particularly, after bone metastasis of lung cancer occurs, the vaccine can effectively inhibit tumor growth, activate inherent immunity and adaptive response of a body by means of mPLA cooperating with mRNA immunotherapy, and cooperatively resist tumors..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 07. Apr. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
YANG JIANHONG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-04-07, Last update posted on www.tib.eu: 2023-09-19, Last updated: 2023-09-22 |
|---|
| Patentnummer: |
CN115920019 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017957478 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017957478 | ||
| 003 | DE-627 | ||
| 005 | 20230929132047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230929s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017957478 | ||
| 035 | |a (EPA)CN115920019 | ||
| 035 | |a (EPA)86650142 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a YANG JIANHONG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MRNA vaccine for treating lung cancer and bone metastasis thereof as well as preparation method and application of mRNA vaccine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-04-07, Last update posted on www.tib.eu: 2023-09-19, Last updated: 2023-09-22 | ||
| 520 | |a The invention discloses an mRNA (messenger Ribonucleic Acid) vaccine for treating lung cancer and bone metastasis thereof as well as a preparation method and application of the mRNA vaccine. Belongs to the technical field of nano-drug preparations and nucleic acid vaccines. The vaccine can realize co-entrapment of the TLR4 agonist monophosphoryl lipid A (mPLA) and mRNA (messenger ribonucleic acid). The particle size is 60-600nm, the Zeta potential is + 8 to + 37mV, the encapsulation efficiency is 60-93%, and the mRNA drug loading capacity is 7.5-20%. The mRNA vaccine constructed by the invention can be administered in a subcutaneous/muscle/nasal mucosa way, stimulate DCs cells to be mature, polarize M2 type macrophages into M1 type macrophages and activate the ADCC effect of NK cells, and multiple immune pathways synergistically play an anti-tumor treatment effect. Particularly, after bone metastasis of lung cancer occurs, the vaccine can effectively inhibit tumor growth, activate inherent immunity and adaptive response of a body by means of mPLA cooperating with mRNA immunotherapy, and cooperatively resist tumors. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MA SHIJIE |4 aut | |
| 700 | 0 | |a ZUO WENBAO |4 aut | |
| 700 | 0 | |a GUO JUESHUO |4 aut | |
| 700 | 0 | |a MAI YAPING |4 aut | |
| 700 | 0 | |a YU NA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 07. Apr. |
| 773 | 1 | 8 | |g year:2023 |g day:07 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86650142/publication/CN115920019A1?q=CN115920019 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 07 |c 04 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 07 |c 04 | ||